FDA Warns Supplement Maker For Misbranding, Procedural Violations

Drug Industry Daily
A A
The FDA warned supplement manufacturer Sanapac for GMP violations, adulterated products and misbranding following two inspections in late 2016.

To View This Article:

Login

Subscribe To Drug Industry Daily